Special Issue

Vaccinology of Influenza Infection

Message from the Guest Editor

Despite decades of research on influenza, highly efficacious vaccines are not always available. This has been an intense area of research. For example, as human vaccines are reformulated every year and carry a risk of mismatch, the creation of a universal influenza vaccine is highly desirable. Population studies continue to measure influenza vaccine efficacy in different target populations and may highlight areas that require improvement, such as vaccination in the elderly or in specific ethnic groups. In the last decade, vaccine uptake has also been a profound issue around the world, and it will be important to identify specific reasons that contribute to the choice not to vaccinate and to address these reasons. Articles related to avian influenza vaccines, improvements to vaccine production, animal/human models of influenza, and delivery methods are welcome in this Special Issue.

Guest Editor

Dr. Andrea Kroeker

Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, SK S7N5E3, Canada

Deadline for manuscript submissions

closed (30 June 2021)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/41397

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

